Please login to the form below

Not currently logged in
Email:
Password:

Takeda wins UK approval for cancer drug

Takeda's bone cancer treatment Mepact has won the backing of the UK's National Institute for Health and Clinical Excellence

Takeda Pharmaceutical won the backing of the UK's National Institute for Health and Clinical Excellence (NICE) for its Mepact (mifamurtide) drug, for the treatment of high-grade resectable non-metastic osteosarcoma.

Mepact is approved for use with chemotherapy after surgery for bone cancers that have not spread. The approval is conditional on Takeda providing a price discount, which it has agreed to do, according to NICE.

The agency reversed a decision from 2010 in which it rejected the drug. The initial economic analysis may not have adequately captured the health-related quality of life from the drug, NICE said.

The terms of the discount have not been disclosed at Takeda's request.

Takeda acquired the rights to Mepact when it purchased IDM Pharma in May, 2009.

7th September 2011

From: Healthcare

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
KnowledgePoint360 Group

KnowledgePoint360's medical communications expertise helps healthcare providers improve patient care, and helps pharma and biotech companies inform clinicians about important...

Latest intelligence

Easier access to medicines in the UK?
Cutting through the NICE value-based assessment consultation to find out what’s at stake...
Exploring MINT: Part 3 - Nigeria
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria....
BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....